GEO series

Synergistic Stromal Remodeling and Dual Chemo-Immunotherapy in Pancreatic Cancer: A Two-Stage Losartan-Primed followed Nanocarrier Strategy for Tumor Microenvironment Reprogramming

GSE306986 Mus musculus (mouse) RNA-seq (gene expression) 24 samples Submitted 2025/12/31 Platform GPL9185

At a glance

RNA-seq (gene expression) · mouse · 24 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Mus musculus (mouse)
Samples: 24 samples: 6 × Muscle,PBS,24day, vs 6 × Muscle,GEM,24day, vs 6 × Muscle,IGEL,24day, vs 6 × Muscle,LIGEL,24day,Groups are read from the sample names, not from the paper. Check the list below.
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.

Summary (written by the submitters)

Pancreatic ductal adenocarcinoma (PDAC) is marked by a dense, fibrotic stroma that hinders drug delivery and promotes an immunosuppressive microenvironment. We developed a two-stage therapeutic strategy (LIGEL) that combines losartan-mediated stromal preconditioning with the targeted delivery of a hybrid nanocarrier (IGEL) co-loaded with gemcitabine and IL-12 circRNA.

Read the full summary ↓

The efficacy of this approach was evaluated in vitro and in vivo, with RNA sequencing used to explore transcriptomic changes in the tumor microenvironment after treatment. Losartan pretreatment significantly reduced extracellular matrix deposition and cancer-associated fibroblast activation, enhancing cellular uptake and tumor penetration. This resulted in notable tumor growth inhibition, prolonged survival, and minimized gemcitabine-associated systemic toxicity. Transcriptomic analysis revealed tumor cell depletion and immune microenvironment activation. These findings highlight the potential of losartan-primed nanotherapy to reprogram the tumor microenvironment and improve the efficacy of combined chemotherapy-immunotherapy.

This dataset

Open GSE306986 in finder → Find more mouse RNA-seq datasets →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE306986_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1314085 and SRA study SRP616428. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗

Study design

6 × Muscle,PBS,24day, vs 6 × Muscle,GEM,24day, vs 6 × Muscle,IGEL,24day, vs 6 × Muscle,LIGEL,24day,

Supports a between-group comparison across 24 samples.

How we read this: 4 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study

GSM9213468 Muscle,PBS,24day,rep1 Muscle,PBS,24day,
GSM9213469 Muscle,PBS,24day,rep2 Muscle,PBS,24day,
GSM9213470 Muscle,PBS,24day,rep3 Muscle,PBS,24day,
GSM9213471 Muscle,PBS,24day,rep4 Muscle,PBS,24day,
GSM9213472 Muscle,PBS,24day,rep5 Muscle,PBS,24day,
GSM9213473 Muscle,PBS,24day,rep6 Muscle,PBS,24day,
GSM9213474 Muscle,GEM,24day,rep1 Muscle,GEM,24day,
GSM9213476 Muscle,GEM,24day,rep2 Muscle,GEM,24day,
GSM9213477 Muscle,GEM,24day,rep3 Muscle,GEM,24day,
GSM9213478 Muscle,GEM,24day,rep4 Muscle,GEM,24day,
GSM9213479 Muscle,GEM,24day,rep5 Muscle,GEM,24day,
GSM9213480 Muscle,GEM,24day,rep6 Muscle,GEM,24day,
GSM9213481 Muscle,IGEL,24day,rep1 Muscle,IGEL,24day,
GSM9213482 Muscle,IGEL,24day,rep2 Muscle,IGEL,24day,
GSM9213484 Muscle,IGEL,24day,rep3 Muscle,IGEL,24day,
GSM9213485 Muscle,IGEL,24day,rep4 Muscle,IGEL,24day,
GSM9213486 Muscle,IGEL,24day,rep5 Muscle,IGEL,24day,
GSM9213487 Muscle,IGEL,24day,rep6 Muscle,IGEL,24day,
GSM9213488 Muscle,LIGEL,24day,rep1 Muscle,LIGEL,24day,
GSM9213489 Muscle,LIGEL,24day,rep2 Muscle,LIGEL,24day,
GSM9213490 Muscle,LIGEL,24day,rep3 Muscle,LIGEL,24day,
GSM9213491 Muscle,LIGEL,24day,rep4 Muscle,LIGEL,24day,
GSM9213492 Muscle,LIGEL,24day,rep5 Muscle,LIGEL,24day,
GSM9213493 Muscle,LIGEL,24day,rep6 Muscle,LIGEL,24day,

Datasets on a similar topic

GSE278100 Foxa1-Mediated Chromatin Remodeling and Enhancer Reprogramming Promotes Gemcitabine Resistance in Pancreatic Cancer 54 samples shares reprogramming, remodeling, pancreatic
GSE218178 Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance 183 samples shares microenvironment, pancreatic
GSE259380 TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody induces tumor regression through profound tumor microenvironment remodeling and strong antitumor adaptive immune response [RNA-seq] 149 samples shares microenvironment, remodeling
GSE288530 Microenvironmental arginine restriction sensitizes pancreatic cancers to polyunsaturated fatty acids by suppression of lipid synthesis 18 samples shares microenvironment, pancreatic
GSE269680 CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma (spatial) 15 samples shares microenvironment, pancreatic
GSE268822 Transcriptional landscapes underlying Notch-induced lineage conversion and reprogramming of mammary cells 840 samples shares reprogramming
GSE305266 The cortical microenvironment drives early immune organization and controls early osteoclastogenesis in bone healing 90 samples shares microenvironment
GSE316139 Studying the role of humanized-TLR8 on immune cell dynamics in the placental microenvironment in a spontaneous mouse model of aPL-induced pregnancy loss 57 samples shares microenvironment

Search all mouse RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.